BioLife CMO sells 353 shares under 10b5-1 plan

BioLife Solutions Inc. Chief Marketing Officer Todd Berard reported an open-market sale of 353 shares of common stock at $20.74 per share on March 3, 2026.

Rhea-AI Filing Summary

BioLife Solutions Inc. Chief Marketing Officer Todd Berard reported an open-market sale of 353 shares of common stock at $20.74 per share on March 3, 2026. After this transaction, he directly held 165,940 shares of BioLife Solutions common stock.

According to the footnote, this sale was executed under a pre-established Rule 10b5-1(c) trading plan, adopted effective February 24, 2022. The plan was designed to satisfy tax withholding obligations related to the vesting of restricted stock, indicating the sale was part of a planned, tax-driven process rather than a discretionary trade.

Insider Trade Summary

Net Seller: 353 shares

Net Sell 1 txn

Insider Berard Todd

Role Chief Marketing Officer

Sold 353 shs ($7K)

Type	Security	Shares	Price	Value
Sale	Common Stock	353	$20.74	$7K

Holdings After Transaction: Common Stock — 165,940 shares (Direct)

Footnotes (1)

1. F1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BLFS Chief Marketing Officer report?

BioLife Solutions’ Chief Marketing Officer Todd Berard reported selling 353 shares of common stock at $20.74 per share. The sale occurred on March 3, 2026 and was described as an open-market or private transaction in common stock.

How many BioLife Solutions (BLFS) shares does the CMO hold after the sale?

After the reported transaction, Todd Berard directly held 165,940 shares of BioLife Solutions common stock. This figure reflects his ownership immediately following the sale of 353 shares disclosed in the Form 4 insider trading report.

Was the BLFS CMO share sale part of a Rule 10b5-1 trading plan?

Yes. The sale was executed under a Rule 10b5-1(c) trading plan adopted effective February 24, 2022. This type of pre-arranged plan allows insiders to systematically sell shares according to preset instructions, helping separate trades from day-to-day discretionary decisions.

Why did the BioLife Solutions CMO sell 353 shares of BLFS stock?

The filing states the sale was made to satisfy tax withholding obligations tied to the vesting of restricted stock. These transactions commonly occur when equity awards vest, and shares are sold to cover associated tax liabilities rather than for portfolio rebalancing.

What price was received in the BLFS CMO’s March 3, 2026 share sale?

The reported transaction price was $20.74 per share for 353 shares of BioLife Solutions common stock. This price reflects the execution level for the open-market or private transaction disclosed in the Form 4 filing.

What role does Todd Berard hold at BioLife Solutions (BLFS)?

Todd Berard is identified as the Chief Marketing Officer of BioLife Solutions Inc. in the insider report. As an executive officer, his transactions in company stock must be disclosed on Form 4, providing transparency into his equity activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 05:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Berard Todd

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Marketing Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		S(1)		353	D	$20.74	165,940	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Remarks:

	/s/ Todd Berard	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.